Exelixis | EXEL - Marktkapitalisierung

Aktienkurs
44.94
Täglich Wechseln
-1.11 -2.41%
Monatlich
5.04%
Jährlich
20.06%
Q2 Prognose
43.98




Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Agios Pharmaceuticals USD 1.59B 745M 2025-12
Akebia Therapeutics USD 427M 297M 2025-12
Amgen USD 176.25B 24.32B 2025-12
AstraZeneca USD 288.15B 55.08B 2025-12
Bayer EUR 36.36B 9.13B 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Bristol-Myers Squibb USD 109.81B 18.01B 2025-12
Cytokinetics USD 7.77B 1.19B 2025-12
Eisai JPY 1.31T 140.95B 2025-12
Eli Lilly USD 1.02T 293.84B 2025-12
Esperion Therapeutics USD 885M 351M 2025-12
Exelixis USD 11.75B 959M 2025-12
Genmab DKK 20.48B 1.02B 2025-12
Glaxosmithkline GBP 99.93B 13.05B 2025-12
Incyte USD 19.39B 2.83B 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
MacroGenics USD 102M 4M 2025-12
Merck USD 261.26B 51.62B 2025-12
Nektar Therapeutics USD 14.34B 13.48B 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novartis USD 292.21B 26.55B 2025-12
Pfizer USD 141.57B 6.48B 2025-12
Sanofi EUR 117.34B 2.45B 2025-12
Takeda JPY 7.64T 774.9B 2025-12
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
Xencor USD 1.09B 256M 2025-12